Quantbot Technologies LP Biocryst Pharmaceuticals Inc Transaction History

Quantbot Technologies LP

  • $2.36 Billion
  • Q3 2024

A detailed history of Quantbot Technologies LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Quantbot Technologies LP holds 371 shares of BCRX stock, worth $2,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
371
Holding current value
$2,778
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$6.41 - $8.69 $2,378 - $3,223
371 New
371 $2,000
Q1 2024

May 06, 2024
BUY
$4.89 - $7.65 $97,311 - $152,235
19,900 Added 829.17%
22,300 $113,000
Q4 2023

Feb 14, 2024
SELL
$4.98 - $6.77 $307,266 - $417,709
-61,700 Reduced 96.26%
2,400 $14,000
Q3 2023

Nov 07, 2023
BUY
$6.71 - $7.92 $430,111 - $507,672
64,100 New
64,100 $453,000
Q1 2023

May 12, 2023
BUY
$7.94 - $11.84 $131,010 - $195,360
16,500 New
16,500 $137,000
Q4 2021

Feb 11, 2022
SELL
$11.18 - $15.46 $556,764 - $769,908
-49,800 Closed
0 $0
Q3 2021

Nov 09, 2021
BUY
$14.21 - $17.65 $677,817 - $841,904
47,700 Added 2271.43%
49,800 $715,000
Q2 2021

Aug 12, 2021
SELL
$9.5 - $17.24 $131,100 - $237,911
-13,800 Reduced 86.79%
2,100 $33,000
Q1 2021

May 14, 2021
BUY
$7.37 - $13.61 $117,183 - $216,399
15,900 New
15,900 $161,000
Q4 2020

Feb 12, 2021
SELL
$3.37 - $8.61 $31,678 - $80,934
-9,400 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$3.43 - $5.53 $32,242 - $51,982
9,400 New
9,400 $32,000

Others Institutions Holding BCRX

# of Institutions
280
Shares Held
172M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email